Amevive(reg) (alefacept) Approved In Canada, Therapy For Psoriasis

Main Category: Eczema / Psoriasis
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 14 Oct 2004 - 14:00 PDT

email to a friend   printer friendly   opinions  

First FDA-Approved Biologic Therapy for Psoriasis Becomes First in Canada

Biogen Idec (NASDAQ: BIIB) today announced that Health Canada has authorized AMEVIVE� (alefacept) for sale in Canada. AMEVIVE, the first biologic approved for psoriasis in Canada, will be marketed for the treatment of patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

AMEVIVE became the first approved biologic therapy for the treatment of moderate-to-severe chronic plaque psoriasis in adults when it was approved in the United States in 2003.

Biogen Idec creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases, and additional information about the company, please visit http://www.biogenidec.com.

For More Information Contact:

Media Contact:
Jose Juves
Associate Director, Public Affairs
Biogen Idec
(617) 914-6524

Investment Community Contact:
Christina Dillon
Senior Manager, Investor Relations
Biogen Idec
(617) 679-2812

• Additional
• References
• Citations